MedTrace Logo

Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms

NCT03451396 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-03-19

No results posted yet for this study

Summary

To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.

Conditions

  • Dry Eye

Interventions

DRUG

Lifitegrast

All subjects meet dry eye inclusion and will be treated with Lifitegrast gtts BID

Sponsors & Collaborators

  • Lifelong Vision Foundation

    lead OTHER

Principal Investigators

  • Jay S Pepose, MD, PhD · Pepose Vision Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-12
Primary Completion
2018-02-01
Completion
2018-03-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03451396 on ClinicalTrials.gov